Faisalabad, 17 September 2026: The signing ceremony of a Memorandum of Understanding (MoU) between Lyallpur Diabetes Foundation (LDF) and Highnoon Laboratories Limited was held at Faisalabad Serena. The MoU is intended to strengthen collaboration in diabetes care, patient engagement, and medication adherence.

Representatives

Lyallpur Diabetes Foundation (LDF)

• Prof. Dr. Aamir Shaukat — Patron
• Dr. Ahmad Shahzad — President and Founder
• Dr. Ijaz Anwer — General Secretary

Highnoon Laboratories Limited

• Dr. Azfar Abbas — Chief Commercial Officer
• Highnoon team

Patient adherence

The meeting discussed the importance of improving patient adherence, with reference to World Health Organization (WHO) data on the impact of adherence on treatment effectiveness and clinical outcomes.

Medherence Portal

It was proposed to add a patient feedback feature within the Medherence Portal to strengthen patient engagement, collect useful feedback, and support continuous improvement of the programme.

The use of collected patient data for future research, particularly on medication adherence and patient outcomes, was also discussed, subject to applicable ethical, privacy, and data-protection requirements.

The provision of government-issued laptops was acknowledged as support for smooth, efficient, and timely patient enrolment and data management through the Medherence Portal.

Continued collaboration

Both organisations acknowledged the importance of continued collaboration under the MoU to support improved patient adherence, digital patient engagement, and better diabetes care outcomes.